Predictive cytogenetic biomarkers for colorectal neoplasia in medium risk patients • JML Journal of Medicine and Life

2015, Volume 8, Issue 3, pp 398 – 403

Predictive cytogenetic biomarkers for colorectal neoplasia in medium risk patients

Issues

Special Issues

Authors and Affiliations

Ionescu EM ^*

Nicolaie T ^*

Ionescu MA ^**

Becheanu G ^*

Andrei F ^*

Diculescu M ^*

Ciocirlan M ^*

* *“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

** **Genetic Lab, Bucharest, Romania

Correspondence to: Ionescu Elena Mirela, MD, PhD, Assistant Prof., Gastroenterology Department, Elias Emergency Hospital, 17 Marasti Blvd., District 1, Bucharest, Romania Phone/ Fax: + 403161600, E-mail: mirela.ionescu80@gmail.com

Abstract

Rationale: DNA damage and chromosomal alterations in peripheral lymphocytes parallels DNA mutations in tumor tissues.

Objective: The aim of our study was to predict the presence of neoplastic colorectal lesions by specific biomarkers in “medium risk” individuals (age 50 to 75, with no personal or family of any colorectal neoplasia).

Methods and Results: We designed a prospective cohort observational study including patients undergoing diagnostic or opportunistic screening colonoscopy. Specific biomarkers were analyzed for each patient in peripheral lymphocytes – presence of micronuclei (MN), nucleoplasmic bridges (NPB) and the Nuclear Division Index (NDI) by the cytokinesis-blocked micronucleus assay (CBMN). Of 98 patients included, 57 were “medium risk” individuals. MN frequency and NPB presence were not significantly different in patients with neoplastic lesions compared to controls. In “medium risk” individuals, mean NDI was significantly lower for patients with any neoplastic lesions (adenomas and adenocarcinomas, AUROC 0.668, p 00.5), for patients with advanced neoplasia (advanced adenoma and adenocarcinoma, AUROC 0.636 p 0.029) as well as for patients with adenocarcinoma (AUROC 0.650, p 0.048), for each comparison with the rest of the population. For a cut-off of 1.8, in “medium risk” individuals, an NDI inferior to that value may predict any neoplastic lesion with a sensitivity of 97.7%, an advanced neoplastic lesion with a sensitivity of 97% and adenocarcinoma with a sensitivity of 94.4%.

Discussion: NDI score may have a role as a colorectal cancer-screening test in “medium risk” individuals.

Abbreviations: DNA = deoxyribonucleic acid; CRC = colorectal cancer; EU = European Union; WHO = World Health Organization; FOBT = fecal occult blood test; CBMN = cytokinesis-blocked micronucleus assay; MN = micronuclei; NPB = nucleoplasmic bridges; NDI = Nuclear Division Index; FAP = familial adenomatous polyposis; HNPCC = hereditary non-polypoid colorectal cancer; IBD = inflammatory bowel diseases; ROC = receiver operating characteristics; AUROC = area under the receiver operating characteristics curve.

Keywords

colorectal cancerscreeningbiomarkerscytokinesisnuclear division index

Preview

JMedLife-08-398

Download PDF

About this article

PMC ID: 4556926
PubMed ID: 26351547
DOI:

Article Publishing Date (print): Jul-Sep 2015
Available Online:

Journal information

ISSN Printing: 1844-122X
ISSN Online: 1844-3117
Journal Title: Journal of Medicine and Life

Copyright License: Open Access

This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.